Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1441-1446

  Bab, Itai ^a   Smoum, Reem ^a   Bradshaw, Heather ^b   Mechoulam, Raphael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b INDIANA UNIVERSITY   (United States)

Author keywords

anandamide; bone formation; bone mass; bone remodelling; bone resorption; CB 1; CB 2; fatty acid amide hydrolase; fatty acid amides; G protein coupled receptors; GPR55; oleoyl ethanolamide; oleoyl serine; osteoblast; osteoclast; osteoporosis; stearoyl ethanolamide

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; LONG CHAIN FATTY ACID; N OLEOYLETHANOLAMINE; STEAROYLETHANOLAMIDE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; AMIDE; BETA 2 ADRENERGIC RECEPTOR; CELL PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; LIPOPROTEIN LIPASE; LIPOPROTEIN LIPASE ALPHA; LIPOPROTEIN LIPASE BETA; MAPKAPK2 PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEOYL ETHANOLAMIDE; OLEOYL SERINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STEAROYL ETHANOLAMIDE;

BIOSYNTHESIS; BONE METABOLISM; BONE TISSUE; CANCER PAIN; CATABOLISM; DRUG INHIBITION; HUMAN; LIPIDOMICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKELETAL LIPIDOMICS; BONE REMODELING; CANNABINOID 1 RECEPTOR GENE; CANNABINOID 2 RECEPTOR GENE; CHROMOSOME 1P; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENE LOCUS; METABOLIC REGULATION; PATHOGENESIS; PROTEIN LOCALIZATION; RECEPTOR BINDING; RECEPTOR GENE; SIGNAL TRANSDUCTION; UPREGULATION;

AMIDES; ANIMALS; BONE AND BONES; BONE RESORPTION; ENDOCANNABINOIDS; FATTY ACIDS; HUMANS; OSTEOGENESIS;

EID: 79960313458     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01474.x     Document Type: Review

References (53)

1. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al,. (2003). TSH is a negative regulator of skeletal remodeling. Cell 115: 151-162. (Pubitemid 37329579)
2. Araujo AM, Buschang PH, Melo AC, (2004). Adaptive condylar growth and mandibular remodelling changes with bionator therapy-an implant study. Eur J Orthod 26: 515-522. (Pubitemid 41296628)
3. Astarita G, Geaga J, Ahmed F, Piomelli D, (2009). Targeted lipidomics as a tool to investigate endocannabinoid function. Int Rev Neurobiol 85: 35-55.
4. Bab I, (2005). The skeleton: stone bones and stoned heads? In:, Mechoulam R, (ed.). Cannabinoids as Therapeutics. Milestones in Drug Therapy Series. Birkhäuser Verlag: Basel, pp. 201-206.
5. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A, (2008). Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 1: 69-74. (Pubitemid 351552679)
6. Bellows CG, Aubin JE, Heersche JN, Antosz ME, (1986). Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38: 143-154. (Pubitemid 16160917)
7. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V, (2001). Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 98: 6402-6406. (Pubitemid 32488249)
8. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ, (1984). Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1: 1091-1093. (Pubitemid 14100805)
9. Connor M, Vaughan CW, Vandenberg RJ, (2010). N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol 160: 1857-1871.
10. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, et al,. (2008). Modulation of osteoclastogenesis by fatty acids. Endocrinology 149: 5688-5695.
11. 2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160: 561-573.
12. Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyt MP, et al,. (1998). First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet 6: 151-157. (Pubitemid 28197339)
13. Devoto M, Specchia C, Li HH, Caminis J, Tenenhouse A, Rodriguez H, et al,. (2001). Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet 10: 2447-2452. (Pubitemid 33069550)
14. Devoto M, Spotila LD, Stabley DL, Wharton GN, Rydbeck H, Korkko J, et al,. (2005). Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet 13: 781-788. (Pubitemid 40846851)
15. Griffith JF, Yeung DK, Ahuja AT, Choy CW, Mei WY, Lam SS, et al,. (2009). A study of bone marrow and subcutaneous fatty acid composition in subjects of varying bone mineral density. Bone 44: 1092-1096.
16. Hansen HS, (2010). Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224: 48-55.
17. Huang QY, Li GH, Kung AW, (2009). Multiple osteoporosis susceptibility genes on chromosome 1p36 in Chinese. Bone 44: 984-988.
18. Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al,. (2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11: 774-779. (Pubitemid 41021210)
19. Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, et al,. (2009). Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 10: 139-147.
20. Jee WS, Ma YF, (1997). The in vivo anabolic actions of prostaglandins in bone. Bone 21: 297-304. (Pubitemid 27454082)
21. Jiang S, Alberich-Jorda M, Zagozdzon R, Parmar K, Fu Y, Mauch P, et al,. (2011). Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood 117: 827-838.
22. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, et al,. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14: 3389-3396. (Pubitemid 41672123)
23. Karsak M, Malkin I, Toliat MR, Kubisch C, Nürnberg P, Zimmer A, et al,. (2009). The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. Hum Genet 126: 629-636.
24. 1 activation and TRPV1 inhibition. J Anesth 24: 328-332.
25. 1 receptor knockout mice. Science 283: 401-404.
26. Lee NJ, Herzog H, (2009). NPY regulation of bone remodelling. Neuropeptides 43: 457-463.
27. Movahed P, Jönsson BA, Birnir B, Wingstrand JA, Jørgensen TD, Ermund A, et al,. (2005). Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 280: 38496-38504. (Pubitemid 43853748)
28. 2, regulates bone mass. Proc Natl Acad Sci USA 103: 696-701. (Pubitemid 43153088)
29. 2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 26: 308-316.
30. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al,. (2007). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
31. Piomelli D, Astarita G, Rapaka R, (2007). A neuroscientist's guide to lipidomics. Nat Rev Neurosci 8: 743-754. (Pubitemid 47462119)
32. 2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res 45: 504-511.
33. 1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 11: 273-285.
34. Robling AG, Castillo AB, Turner CH, (2006). Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 8: 455-498. (Pubitemid 44314825)
35. Rosen CJ, (1997). Insulin-like growth factor-I and parathyroid hormone: potential new therapeutic agents for the treatment of osteoporosis. Expert Opin Investig Drugs 6: 1193-1198. (Pubitemid 27395804)
36. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al,. (2009). The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44: 476-484.
37. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, De Petrocellis L, et al,. (2011). The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone 48: 997-1007.
38. 2 receptors. Calcif Tissue Int 80: 50-59. (Pubitemid 46098877)
39. Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, et al,. (2010). Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci USA 107: 17710-17715.
40. Spener F, Lagarde M, Geloen AF, Spener M, Lagarde A, Geloen M, (2003). What is lipidomics? Eur J Lipid Sci Technol 105: 481-482.
41. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al,. (2006). FSH directly regulates bone mass. Cell 125: 247-260.
42. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al,. (2002). Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317. (Pubitemid 35345151)
43. 1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70: 786-792. (Pubitemid 44268435)
44. 1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 22: 285-294.
45. Tan B, Yu YW, Monn MF, Hughes HV, O'Dell DK, Walker JM, (2009). Targeted lipidomics approach for endogenous N-acyl amino acids in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2890-2894.
46. Ueda N, Tsuboi K, Uyama T, (2010). Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-1285.
47. Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, et al,. (2008). Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 40: 789-793. (Pubitemid 351748871)
48. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, et al,. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511-16516.
49. Yamada Y, Ando F, Shimokata H, (2007). Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 19: 791-801.
50. Zhang RW, Supowit SC, Xu X, Li H, Christensen MD, Lozano R, et al,. (1995). Expression of selected osteogenic markers in the fibroblast-like cells of rat marrow stroma. Calcif Tissue Int 56: 283-291.
51. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ, Ng KW, (1994). In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res 9: 1489-1499. (Pubitemid 24268862)
52. 1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785. (Pubitemid 29234695)
53. Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z, (2002). CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB J 16: 274-282. (Pubitemid 34195289)